Cannabinoids based pharmaceutical composition
US11395813B1 · kind B1 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 15, 2022 |
| Grant date | Jul 26, 2022 |
| Priority date | — |
| Expiry date | Feb 15, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/35
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pain relief composition has a base with cannabinoids in a range of 2% to 15% by weight of the pharmaceutical composition is present with ashwagandha extracts. Dimethyl sulfoxide (DMSO) in a range of 0.01% to 2% by weight of the pharmaceutical composition is further used. The cannaoids are one of cannabidiol (CBD) and tetrahydrocannabinol (THC).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.